An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Silence Therapeutics plc, trading as SLN on Nasdaq, announced it will release its financial and business results for Q4 and the full year ending December 31, 2021 on March 17, 2022. A conference call will take place at 8:00 a.m. EDT (12:00 p.m. GMT) on the same day, offering insights into the Company’s performance and updates. Investors can access the live webcast via the Company’s website. Silence specializes in developing siRNA therapeutics targeting diseases with unmet medical needs, including cardiovascular and hematological conditions.
Positive
None.
Negative
None.
LONDON--(BUSINESS WIRE)--
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 17, 2022.
Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT on Thursday, March 17, to discuss the Company’s financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company’s website.
Details of the webcast and conference call:
Dial-in details:
New York, United States: +1 646 741 3167
United States: 1 877 870 9135
London, United Kingdom: +44 2071 928338
United Kingdom: 08002796619
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
